Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.47 |
| ▸ | CXCR4 | P61073 | 3/20 | 0.39 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.39 |
| ▸ | CA2 | P00918 | 1/20 | 0.33 |
| ▸ | CHKA | P35790 | 1/20 | 0.33 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.33 |
| ▸ | PHGDH | O43175 | 1/20 | 0.33 |
| ▸ | HRH1 | P35367 | 1/20 | 0.33 |
| ▸ | USP2 | O75604 | 1/20 | 0.32 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.32 |
| ▸ | SOS1 | Q07889 | 1/20 | 0.31 |
| ▸ | SOS2 | Q07890 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4135000 | 1.00 | ALDH1A1 (0.47) | ALDH1A1CXCR4SMN1; SMN2CA2CHKA | |
| N-Methylpiperidine SCHEMBL9009614 | 0.97 | ALDH1A1 (0.53) | ALDH1A1CXCR4SMN1; SMN2CA2CHKA | |
| SCHEMBL17519525 | 0.97 | ALDH1A1 (0.44) | ALDH1A1CXCR4SMN1; SMN2CA2CHKA | |
| SCHEMBL14299867 | 0.97 | ALDH1A1 (0.53) | ALDH1A1CXCR4SMN1; SMN2CA2CHKA | |
| SCHEMBL16790161 | 0.97 | ALDH1A1 (0.53) | ALDH1A1CXCR4SMN1; SMN2CA2CHKA | |
| SCHEMBL14299960 | 0.97 | ALDH1A1 (0.53) | ALDH1A1CXCR4SMN1; SMN2CA2CHKA | |
| N-Methylpiperidine SCHEMBL1038414 | 0.97 | ALDH1A1 (0.53) | ALDH1A1CXCR4SMN1; SMN2CA2CHKA | |
| SCHEMBL256535 | 0.94 | ALDH1A1 (0.50) | ALDH1A1CXCR4SMN1; SMN2CA2CHKA | |
| SCHEMBL6632282 | 0.94 | — | — | |
| SCHEMBL9419378 | 0.94 | ALDH1A1 (0.50) | ALDH1A1CXCR4SMN1; SMN2CA2CHKA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20090005413-A1 | Novel Salt of Montelukast | INSTYTUT FARMACEUTYCZNY (PL) | 2009-01-01 | — | — | US | disclosed |
| EP-1853563-A1 | SALT OF MONTELUKAST WITH TERT.-BUTYLAMINE | INSTYTUT FARMACEUTYCZNY (PL) | 2007-11-14 | — | — | EP | disclosed |
| WO-2006043846-A1 | SALT OF MONTELUKAST WITH TERT.-BUTYLAMINE | INSTYTUT FARMACEUTYCZNY (PL) | 2006-04-27 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090005413-A1 | Novel Salt of Montelukast | TST, LTC4S, TSLP | ALDH1A1 2837/4885CXCR4 2481/4885SMN1; SMN2 3136/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.